EUVIMEDEUVIMED entdecken
Open Access

Recent COVID-19 Vaccination and Risk of SARS-CoV-2 Transmission

Sara C Benist, Sarah E Smith-Jeffcoat, H Keipp Talbot, Yuwei Zhu, Jonathan E Schmitz, Theresa A Scott, Melissa S Stockwell, Son H McLaren, Ellen D Sano, Celibell Y Vargas, Ana Valdez de Romero, Helen Y Chu und 8 weitere

JAMA Network Open · 2026

DOI: 10.1001/jamanetworkopen.2026.12609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2026. Verfasst von Sara C Benist und 19 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, Vaccination, Vaccine Efficacy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance COVID-19 vaccine effectiveness (VE) is typically studied in the context of reducing the risk of severe illness and death. Few studies have estimated VE in preventing transmission and infection with current levels of SARS-CoV-2 population immunity.

Objective

To estimate COVID-19 VE against transmission and infection within households. Design, Setting, and Participants This cohort study was a prospective, case-ascertained household transmission study (performed in New York, Tennessee, and Washington) in which the first household member with confirmed SARS-CoV-2 infection (primary case participant) was identified through outpatient settings and enrolled with their household contacts from January 1, 2024, to January 31, 2025. Participants provided demographic information, and COVID-19 vaccination history was verified by study staff. After enrollment, participants were instructed to collect daily nasal swabs for 10 days regardless of symptoms. Nasal swabs were tested for SARS-CoV-2 via reverse transcription–polymerase chain reaction. Exposure COVID-19 vaccination history in primary case participants and household contacts categorized as time from most recent vaccination to COVID-19 onset in the primary case participant (≤6 months, 7-12 months, >12 months, and unvaccinated [reference group]). Main Outcomes and Measures Household contacts were considered infected if at least 1 swab tested positive for SARS-CoV-2. Secondary infection risk was calculated as the number of infected contacts divided by the total number of contacts. Adjusted relative risk (ARR) of infection was estimated using a multivariable Poisson regression model, with generalized estimating equations accounting for household-level clustering. Vaccine effectiveness was calculated as 1 minus the ARR of the primary case participant and household contacts’ vaccination status to estimate VE against transmission and against infection, respectively.

Results

This analysis included 362 primary case participants (median [IQR] age, 35 [10-53] years; 199 female [55.0%]) and 763 household contacts (median [IQR] age, 29 [12-44] years; 399 female [52.3%]). SARS-CoV-2 infection was detected in 476 household contacts during follow-up for a secondary infection risk of 62.4% (95% CI, 58.7%-65.5%). Household contacts of primary case participants vaccinated 6 months or less before onset had a lower infection risk compared with contacts of unvaccinated primary case participants (ARR, 0.57 [95% CI, 0.35-0.93]). There was no statistically significant difference in infection risk based on vaccination status of household contacts. Conclusions and Relevance In this cohort study, recent COVID-19 vaccination was associated with a reduced risk of SARS-CoV-2 transmission. These findings suggest that COVID-19 vaccination may have an indirect benefit of decreasing transmission and thus reducing overall exposure to SARS-CoV-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19VaccinationVaccine EfficacyHumansFemaleMaleAdultProspective StudiesSARS-CoV-2Middle AgedFamily CharacteristicsTennesseeUnvaccinated PersonsYoung AdultWashingtonNew YorkAdolescent

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee.
  • Vanderbilt University Medical Center, Nashville, Tennessee.
  • Columbia University Irving Medical Center, New York, New York.
  • University of Washington, Seattle, Washington.
  • Department of Internal Medicine, University of Michigan, Ann Arbor.

Zitieren

APA

Benist, S. C., Smith-Jeffcoat, S. E., Talbot, H. K., Zhu, Y., Schmitz, J. E., Scott, T. A., Stockwell, M. S., McLaren, S. H., Sano, E. D., Vargas, C. Y., Valdez de Romero, A., Chu, H. Y., Englund, J. A., Clark, E., MacMillan, M. P., Lauring, A. S., Oyegun, E. I., Bertumen, J. B., Grijalva, C. G., & Kirking, H. L. (2026). Recent COVID-19 Vaccination and Risk of SARS-CoV-2 Transmission. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.12609

Vancouver

Benist SC, Smith-Jeffcoat SE, Talbot HK, Zhu Y, Schmitz JE, Scott TA, et al. Recent COVID-19 Vaccination and Risk of SARS-CoV-2 Transmission. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.12609

BibTeX
@article{Benist2026,
  author = {Benist, Sara C and Smith-Jeffcoat, Sarah E and Talbot, H Keipp and Zhu, Yuwei and Schmitz, Jonathan E and Scott, Theresa A and Stockwell, Melissa S and McLaren, Son H and Sano, Ellen D and Vargas, Celibell Y and Valdez de Romero, Ana and Chu, Helen Y and Englund, Janet A and Clark, Erica and MacMillan, Melissa P and Lauring, Adam S and Oyegun, E Ivy and Bertumen, J Bradford and Grijalva, Carlos G and Kirking, Hannah L},
  title = {Recent COVID-19 Vaccination and Risk of SARS-CoV-2 Transmission},
  journal = {JAMA Network Open},
  year = {2026},
  doi = {10.1001/jamanetworkopen.2026.12609}
}
Kostenlos starten →